A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 11, 2022

Primary Completion Date

June 21, 2022

Study Completion Date

July 12, 2022

Conditions

Healthy

Interventions

DRUG

CT-L01

FDC tablet, single dose, oral administration

DRUG

Alogliptin Benzoate 25 mg

Alogliptin Benzoate 25 mg, oral administration

DRUG

Metformin HCl XR 1,000 mg

Metformin HCl XR 1,000 mg, oral administration

Trial Locations (1)

Chungnam National University Hospital, Daejeon